Kopran Limited — Updates, 20-03-2025: Press Release

The Board has approved the merger of Kopran Laboratories Limited with Kopran Limited, pending necessary approvals from the Stock Exchange, SEBI, and shareholders. The merger is structured as a share exchange ratio, where 100 equity shares of Kopran Limited will be allocated for every 45 shares of Kopran Laboratories.

Kopran Laboratories has shown significant growth, with FY 23-24 revenues reaching ₹10,240.47 Cr and an EBITDA margin of 27.60%. The diagnostics market in India, valued at $14 billion and expected to grow at a CAGR of 14%, presents a robust opportunity for Kopran post-merger. This strategic move enhances Kopran’s position in the healthcare sector, leveraging KLL’s established relationships and team for market penetration. Additionally, Kopran plans to utilize its manufacturing capabilities to enhance profitability in the diagnostic segment, making the merger potentially EPS accretive and value-generating for shareholders. Watch closely as this merger unfolds, as it positions Kopran for substantial growth ahead.